Sign in to view content

Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker for the Treatment of Diabetic Macular Edema

Victor Hugo Gonzalez, MD

Video
Published 2024

Related

Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody RG7716 in Diabetic Macular Edema: 36-Week Results From the Phase 2 BOULEVARD Clinical Trial
Rishi P. Singh, MD
Annual Meeting Talks
2018
Randomized Trial of Initiating Therapy With Aflibercept, Laser, or Observation for Eyes With Good Vision and Center-Involved Diabetic Macular Edema
Carl W. Baker, MD, FASRS
Updates from the Field
2019
Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more